All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) PDL1 (TPS >50%) PDL1 < 25% PDL1 >25% smoker (current or former) smoker (Current) smoker (Former) smoker (never) stage III (locally advanced) stage IIIa stage IIIb stage IV (metastatic) Teff high Teff low
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), anti-PD-(L)1 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.63 [0.42; 0.94]
CAURAL (EXPLORATORY), 2019 2.60 [0.39; 17.16]
CheckMate 017, 2015 0.59 [0.44; 0.79]
CheckMate 026 (PDL1>1%), 2016 1.07 [0.86; 1.33]
CheckMate 026 (PDL1>5%), 2016 1.02 [0.80; 1.30]
CheckMate 057, 2015 0.73 [0.59; 0.90]
CheckMate 078, 2019 0.68 [0.52; 0.89]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.78 [0.60; 1.02]
EMPOWER lung1 (all population), 2021 0.68 [0.53; 0.87]
EMPOWER lung1 (PDL1>50%), 2021 0.57 [0.42; 0.77]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.83 [0.65; 1.06]
IMpower-110 (TC2/3 or IC2/3), 2020 0.72 [0.52; 0.99]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.40; 0.88]
IMpower-130 (all population), 2019 0.80 [0.65; 0.99]
IMpower-130 (WT), 2019 0.79 [0.64; 0.98]
IMpower-131 (ACnP), 2020 0.88 [0.73; 1.06]
IMpower-150 (ABCP vs BPC WT), 2018 0.78 [0.64; 0.96]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.76 [0.63; 0.92]
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 0.85 [0.71; 1.02]
JAVELIN Lung 200 (all population), 2018 0.90 [0.75; 1.08]
JAVELIN Lung 200 (PDL1 >1%), 2018 0.90 [0.72; 1.12]
KEYNOTE-021, 2016 0.90 [0.42; 1.92]
KEYNOTE-024 (PDL1>50%), 2016 0.60 [0.41; 0.88]
KEYNOTE-042 (PDL1>1%), 2019 0.81 [0.71; 0.93]
KEYNOTE-042 (PDL1>20%), 2019 0.77 [0.64; 0.92]
KEYNOTE-042 (PDL1>50%), 2019 0.69 [0.56; 0.85]
KEYNOTE-189, 2018 0.49 [0.38; 0.64]
KEYNOTE-407, 2018 0.64 [0.49; 0.84]
KEYNOTE-598, 2020 1.08 [0.85; 1.37]
MYSTIC (D ; all population), 2020 0.96 [0.81; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.76 [0.56; 1.03]
OAK (all population), 2016 0.80 [0.70; 0.92]
OAK (PDL1 TC 1/2/3), 2016 0.77 [0.64; 0.92]
ORIENT-11, 2020 0.61 [0.40; 0.93]
PACIFIC, 2017 0.68 [0.47; 0.99]
POPLAR, 2016 0.73 [0.53; 1.00]
0.78 [0.73 ; 0.82 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (all population), 2019, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018, JAVELIN Lung 200 (all population), 2018, JAVELIN Lung 200 (PDL1 >1%), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, ORIENT-11, 2020, PACIFIC, 2017, POPLAR, 2016 36 48% 20,143 moderate critical deaths (OS) (extension)detailed results CheckMate 017, 2015 0.31 [0.14; 0.69]
CheckMate 078, 2019 0.75 [0.61; 0.93]
IMpower-110 (TC3 or IC3), 2020 0.76 [0.53; 1.08]
KEYNOTE-021, 2016 0.71 [0.45; 1.12]
KEYNOTE-024 (PDL1>50%), 2016 0.62 [0.48; 0.81]
KEYNOTE-042 (PDL1>1%), 2019 0.80 [0.71; 0.90]
KEYNOTE-042 (PDL1>20%), 2019 0.75 [0.64; 0.88]
KEYNOTE-042 (PDL1>50%), 2019 0.98 [0.82; 1.18]
KEYNOTE-189, 2018 0.56 [0.45; 0.70]
PACIFIC, 2017 0.72 [0.59; 0.88]
0.73 [0.65 ; 0.82 ] CheckMate 017, 2015, CheckMate 078, 2019, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, PACIFIC, 2017 10 61% 5,429 moderate low PFS (extension)detailed results CheckMate 017, 2015 0.48 [0.24; 0.96]
CheckMate 078, 2019 0.79 [0.64; 0.97]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.72 [0.60; 0.86]
IMpower-110 (TC2/3 or IC2/3), 2020 0.64 [0.50; 0.82]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.43; 0.81]
KEYNOTE-021, 2016 0.54 [0.35; 0.83]
KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.39; 0.65]
KEYNOTE-042 (PDL1>1%), 2019 1.05 [0.93; 1.18]
KEYNOTE-042 (PDL1>20%), 2019 0.95 [0.82; 1.10]
KEYNOTE-042 (PDL1>50%), 2019 0.85 [0.71; 1.01]
KEYNOTE-189, 2018 0.48 [0.40; 0.58]
PACIFIC, 2017 0.55 [0.45; 0.68]
0.68 [0.57 ; 0.80 ] CheckMate 017, 2015, CheckMate 078, 2019, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, PACIFIC, 2017 12 88% 6,311 moderate critical progression or deaths (PFS)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.71 [0.49; 1.03]
CAURAL (EXPLORATORY), 2019 1.10 [0.22; 5.61]
CheckMate 017, 2015 0.62 [0.47; 0.81]
CheckMate 026 (PDL1>1%), 2016 1.17 [0.95; 1.44]
CheckMate 026 (PDL1>5%), 2016 1.15 [0.91; 1.45]
CheckMate 057, 2015 0.92 [0.77; 1.10]
CheckMate 078, 2019 0.77 [0.62; 0.95]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.73 [0.56; 0.95]
EMPOWER lung1 (all population), 2021 0.59 [0.49; 0.72]
EMPOWER lung1 (PDL1>50%), 2021 0.54 [0.43; 0.68]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.77 [0.63; 0.94]
IMpower-110 (TC2/3 or IC2/3), 2020 0.67 [0.52; 0.87]
IMpower-110 (TC3 or IC3), 2020 0.63 [0.45; 0.88]
IMpower-130 (all population), 2019 0.65 [0.54; 0.78]
IMpower-130 (WT), 2019 0.64 [0.54; 0.76]
IMpower-131 (ACnP), 2020 0.71 [0.60; 0.85]
IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 0.51 [0.38; 0.68]
IMpower-150 (ABCP vs BPC WT), 2018 0.62 [0.52; 0.74]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.61 [0.52; 0.72]
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 0.91 [0.78; 1.06]
JAVELIN Lung 200 (all population), 2018 1.16 [0.97; 1.39]
JAVELIN Lung 200 (PDL1 >1%), 2018 1.01 [0.80; 1.28]
KEYNOTE-021, 2016 0.53 [0.31; 0.91]
KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.37; 0.68]
KEYNOTE-042 (PDL1>1%), 2019 1.07 [0.94; 1.21]
KEYNOTE-042 (PDL1>20%), 2019 0.94 [0.80; 1.11]
KEYNOTE-042 (PDL1>50%), 2019 0.81 [0.67; 0.98]
KEYNOTE-189, 2018 0.52 [0.43; 0.63]
KEYNOTE-407, 2018 0.56 [0.45; 0.70]
KEYNOTE-598, 2020 1.06 [0.86; 1.30]
MYSTIC (D ; PDL1>25%), 2020 0.87 [0.59; 1.29]
OAK (all population), 2016 0.96 [0.85; 1.08]
OAK (PDL1 TC 1/2/3), 2016 0.87 [0.74; 1.03]
ORIENT-11, 2020 0.48 [0.36; 0.64]
PACIFIC, 2017 0.52 [0.42; 0.65]
POPLAR, 2016 0.94 [0.72; 1.23]
0.75 [0.68 ; 0.82 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (all population), 2019, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018, JAVELIN Lung 200 (all population), 2018, JAVELIN Lung 200 (PDL1 >1%), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, ORIENT-11, 2020, PACIFIC, 2017, POPLAR, 2016 36 84% 19,677 moderate critical DORdetailed results IMpower-130 (WT), 2019 2.41 [1.27; 4.60]
IMpower-131 (ACnP), 2020 2.14 [1.13; 4.04]
OAK (PDL1 TC 1/2/3), 2016 9.61 [3.07; 30.08]
3.18 [1.53 ; 6.61 ] IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, OAK (PDL1 TC 1/2/3), 2016 3 63% 708 moderate not evaluable objective responses (ORR)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 3.87 [1.55; 9.69]
CAURAL (EXPLORATORY), 2019 0.45 [0.08; 2.40]
CheckMate 017, 2015 2.60 [1.26; 5.35]
CheckMate 026 (PDL1>5%), 2016 0.70 [0.46; 1.06]
CheckMate 057, 2015 1.70 [1.11; 2.61]
CheckMate 078, 2019 4.40 [1.99; 9.74]
EMPOWER lung1 (all population), 2021 2.21 [1.58; 3.10]
EMPOWER lung1 (PDL1>50%), 2021 2.53 [1.32; 4.85]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.89 [0.62; 1.27]
IMpower-110 (TC2/3 or IC2/3), 2020 0.94 [0.59; 1.50]
IMpower-110 (TC3 or IC3), 2020 1.55 [0.86; 2.79]
IMpower-130 (WT), 2019 2.07 [1.48; 2.89]
IMpower-131 (ACnP), 2020 1.42 [1.05; 1.92]
IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 1.96 [1.20; 3.19]
IMpower-150 (ABCP vs BPC WT), 2018 1.88 [1.38; 2.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.95 [1.47; 2.58]
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 1.02 [0.77; 1.35]
JAVELIN Lung 200 (all population), 2018 1.40 [0.92; 2.13]
JAVELIN Lung 200 (PDL1 >1%), 2018 1.76 [1.08; 2.86]
KEYNOTE-021, 2016 3.06 [1.45; 6.45]
KEYNOTE-024 (PDL1>50%), 2016 2.11 [1.31; 3.39]
KEYNOTE-042 (PDL1>1%), 2019 1.04 [0.81; 1.33]
KEYNOTE-042 (PDL1>20%), 2019 1.24 [0.92; 1.66]
KEYNOTE-042 (PDL1>50%), 2019 1.39 [0.99; 1.94]
KEYNOTE-189, 2018 3.88 [2.61; 5.79]
KEYNOTE-407, 2018 2.20 [1.57; 3.09]
KEYNOTE-598, 2020 1.00 [0.72; 1.39]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.43]
OAK (all population), 2016 1.19 [0.85; 1.67]
OAK (PDL1 TC 1/2/3), 2016 1.41 [0.93; 2.14]
ORIENT-11, 2020 2.54 [1.63; 3.97]
PACIFIC, 2017 2.03 [1.36; 3.03]
POPLAR, 2016 0.99 [0.52; 1.91]
1.59 [1.38 ; 1.84 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019, CheckMate 017, 2015, CheckMate 026 (PDL1>5%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018, JAVELIN Lung 200 (all population), 2018, JAVELIN Lung 200 (PDL1 >1%), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, ORIENT-11, 2020, PACIFIC, 2017, POPLAR, 2016 33 75% 18,024 moderate critical objective responses (ORR) (extension)detailed results CheckMate 017, 2015 0.53 [0.19; 1.48]
CheckMate 078, 2019 4.80 [2.14; 10.77]
IMpower-110 (TC3 or IC3), 2020 1.68 [0.94; 3.01]
KEYNOTE-021, 2016 2.80 [1.34; 5.83]
KEYNOTE-024 (PDL1>50%), 2016 1.89 [1.19; 3.02]
KEYNOTE-042 (PDL1>1%), 2019 1.03 [0.81; 1.32]
KEYNOTE-042 (PDL1>20%), 2019 1.21 [0.90; 1.62]
KEYNOTE-042 (PDL1>50%), 2019 1.35 [0.96; 1.88]
KEYNOTE-189, 2018 3.84 [2.58; 5.70]
1.74 [1.21 ; 2.51 ] CheckMate 017, 2015, CheckMate 078, 2019, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 9 84% 4,716 moderate not evaluable AE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.24 [0.01; 5.43]
CAURAL (EXPLORATORY), 2019 1.43 [0.03; 77.69]
CheckMate 057, 2015 0.45 [0.12; 1.77]
EMPOWER lung1 (all population), 2021 0.18 [0.12; 0.27]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.52 [0.27; 1.01]
IMpower-130 (all population), 2019 2.05 [0.29; 14.63]
IMpower-131 (ACnP), 2020 5.12 [1.11; 23.56]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.49 [0.15; 1.65]
KEYNOTE-189, 2018 4.04 [0.36; 44.82]
KEYNOTE-407, 2018 1.20 [0.36; 3.96]
MYSTIC (D ; all population), 2020 0.59 [0.31; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.42 [0.14; 1.22]
OAK (all population), 2016 0.66 [0.39; 1.13]
ORIENT-11, 2020 1.02 [0.03; 30.46]
PACIFIC, 2017 1.66 [0.76; 3.60]
POPLAR, 2016 0.87 [0.26; 2.93]
0.73 [0.45 ; 1.20 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019, CheckMate 057, 2015, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, ORIENT-11, 2020, PACIFIC, 2017, POPLAR, 2016 16 71% 8,885 moderate critical AE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.36 [0.18; 0.75]
CAURAL (EXPLORATORY), 2019 12.38 [1.29; 118.34]
CheckMate 057, 2015 0.42 [0.29; 0.59]
EMPOWER lung1 (all population), 2021 0.19 [0.13; 0.29]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.39 [0.27; 0.55]
IMpower-130 (all population), 2019 1.72 [1.19; 2.47]
IMpower-131 (ACnP), 2020 1.37 [0.98; 1.90]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.14 [0.86; 1.52]
KEYNOTE-189, 2018 1.03 [0.73; 1.45]
KEYNOTE-407, 2018 0.99 [0.70; 1.39]
MYSTIC (D ; all population), 2020 0.81 [0.60; 1.10]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.41]
OAK (all population), 2016 0.51 [0.41; 0.65]
ORIENT-11, 2020 1.13 [0.74; 1.73]
PACIFIC, 2017 1.21 [0.85; 1.72]
POPLAR, 2016 0.60 [0.38; 0.97]
0.77 [0.58 ; 1.04 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019, CheckMate 057, 2015, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, ORIENT-11, 2020, PACIFIC, 2017, POPLAR, 2016 16 90% 8,885 moderate low AE leading to death (grade 5)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 3.27 [0.63; 16.86]
CAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74]
EMPOWER lung1 (all population), 2021 1.24 [0.46; 3.38]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.39; 2.15]
IMpower-130 (all population), 2019 0.94 [0.47; 1.87]
IMpower-131 (ACnP), 2020 2.59 [1.36; 4.92]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.10 [0.60; 2.03]
KEYNOTE-189, 2018 1.13 [0.56; 2.28]
KEYNOTE-407, 2018 1.31 [0.69; 2.49]
MYSTIC (D ; all population), 2020 0.82 [0.38; 1.75]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.20; 2.86]
OAK (all population), 2016 0.67 [0.30; 1.53]
ORIENT-11, 2020 0.31 [0.11; 0.90]
PACIFIC, 2017 0.79 [0.39; 1.60]
POPLAR, 2016 1.15 [0.34; 3.85]
1.05 [0.82 ; 1.34 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, ORIENT-11, 2020, PACIFIC, 2017, POPLAR, 2016 15 21% 8,330 moderate low AE leading to treatment discontinuation (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.63 [0.24; 1.67]
EMPOWER lung1 (all population), 2021 1.62 [0.82; 3.21]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.34 [0.19; 0.61]
IMpower-130 (all population), 2019 1.27 [0.88; 1.85]
IMpower-131 (ACnP), 2020 2.09 [1.45; 3.02]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.46 [1.07; 1.99]
KEYNOTE-189, 2018 2.19 [1.31; 3.65]
KEYNOTE-407, 2018 2.28 [1.45; 3.61]
MYSTIC (D ; all population), 2020 0.72 [0.47; 1.12]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.38; 1.46]
OAK (all population), 2016 0.58 [0.45; 0.75]
ORIENT-11, 2020 0.70 [0.31; 1.55]
PACIFIC, 2017 1.67 [1.01; 2.74]
POPLAR, 2016 0.29 [0.14; 0.61]
1.01 [0.72 ; 1.42 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, ORIENT-11, 2020, PACIFIC, 2017, POPLAR, 2016 14 86% 8,301 moderate low AE leading to treatment discontinuation (grade 3-4)detailed results KEYNOTE-189, 2018 2.04 [1.16; 3.59]
KEYNOTE-407, 2018 2.09 [1.28; 3.39]
MYSTIC (D ; all population), 2020 1.10 [0.64; 1.89]
ORIENT-11, 2020 0.64 [0.26; 1.56]
1.43 [0.89 ; 2.29 ] KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 4 61% 2,283 low not evaluable SAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.73 [0.81; 3.73]
CAURAL (EXPLORATORY), 2019 1.64 [0.32; 8.45]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.99 [0.68; 1.44]
IMpower-130 (all population), 2019 1.69 [1.22; 2.32]
IMpower-131 (ACnP), 2020 2.28 [1.66; 3.14]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.40 [1.05; 1.87]
MYSTIC (D ; PDL1>25%), 2020 1.22 [0.77; 1.94]
PACIFIC, 2017 1.37 [0.95; 1.97]
POPLAR, 2016 1.05 [0.64; 1.73]
1.44 [1.18 ; 1.74 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, MYSTIC (D ; PDL1>25%), 2020, PACIFIC, 2017, POPLAR, 2016 9 47% 4,163 moderate not evaluable SAE (grade 3-4)detailed results CheckMate 017, 2015 0.10 [0.03; 0.33]
OAK (all population), 2016 1.03 [0.80; 1.31]
0.34 [0.03 ; 3.42 ] CheckMate 017, 2015, OAK (all population), 2016 2 93% 1,447 moderate not evaluable STRAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.33; 3.10]
CAURAL (EXPLORATORY), 2019 0.33 [0.01; 10.81]
CheckMate 017, 2015 0.23 [0.11; 0.51]
CheckMate 026 (PDL1>1%), 2016 0.93 [0.60; 1.46]
CheckMate 057, 2015 0.32 [0.19; 0.55]
CheckMate 078, 2019 0.59 [0.34; 1.02]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.75 [1.00; 3.09]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.50 [0.29; 0.85]
IMpower-130 (all population), 2019 2.09 [1.35; 3.24]
IMpower-131 (ACnP), 2020 2.27 [1.46; 3.51]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.43 [1.02; 2.00]
JAVELIN Lung 200 (all population), 2018 0.37 [0.24; 0.57]
KEYNOTE-021, 2016 3.47 [1.25; 9.62]
KEYNOTE-024 (PDL1>50%), 2016 1.05 [0.60; 1.82]
MYSTIC (D ; all population), 2020 0.56 [0.35; 0.90]
MYSTIC (D ; PDL1>25%), 2020 0.38 [0.18; 0.77]
0.82 [0.56 ; 1.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 16 86% 7,274 moderate low STRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.82 [0.50; 1.33]
CheckMate 057, 2015 0.25 [0.14; 0.46]
CheckMate 078, 2019 0.34 [0.18; 0.66]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.05 [1.12; 3.76]
KEYNOTE-021, 2016 5.56 [1.49; 20.67]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.55; 1.72]
MYSTIC (D ; all population), 2020 0.48 [0.28; 0.84]
0.79 [0.43 ; 1.46 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, MYSTIC (D ; all population), 2020 7 85% 3,079 moderate not evaluable TRAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.19 [0.08; 0.46]
CAURAL (EXPLORATORY), 2019 2.33 [0.41; 13.17]
CheckMate 017, 2015 0.22 [0.12; 0.41]
CheckMate 026 (PDL1>1%), 2016 0.20 [0.12; 0.34]
CheckMate 078, 2019 0.35 [0.22; 0.57]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 3.42 [1.76; 6.65]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.27 [0.18; 0.40]
IMpower-130 (all population), 2019 2.00 [1.01; 3.95]
IMpower-131 (ACnP), 2020 1.80 [0.98; 3.28]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.81 [0.43; 1.53]
JAVELIN Lung 200 (all population), 2018 0.29 [0.21; 0.42]
KEYNOTE-021, 2016 0.95 [0.29; 3.12]
KEYNOTE-024 (PDL1>50%), 2016 0.31 [0.16; 0.58]
KEYNOTE-042 (PDL1>1%), 2019 0.19 [0.14; 0.26]
MYSTIC (D ; all population), 2020 0.24 [0.17; 0.34]
MYSTIC (D ; PDL1>25%), 2020 0.21 [0.12; 0.38]
OAK (all population), 2016 0.29 [0.22; 0.39]
PACIFIC, 2017 1.84 [1.33; 2.53]
POPLAR, 2016 0.27 [0.15; 0.51]
0.48 [0.31 ; 0.73 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, PACIFIC, 2017, POPLAR, 2016 19 93% 10,143 moderate low TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.13 [0.05; 0.36]
CAURAL (EXPLORATORY), 2019 7.08 [0.34; 148.71]
CheckMate 017, 2015 0.06 [0.03; 0.13]
CheckMate 026 (PDL1>1%), 2016 0.21 [0.14; 0.31]
CheckMate 057, 2015 0.10 [0.06; 0.16]
CheckMate 078, 2019 0.15 [0.10; 0.24]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.35 [1.53; 3.60]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.19 [0.12; 0.29]
IMpower-130 (all population), 2019 1.79 [1.28; 2.50]
IMpower-131 (ACnP), 2020 1.57 [1.14; 2.15]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.38 [1.04; 1.83]
JAVELIN Lung 200 (all population), 2018 0.12 [0.08; 0.18]
KEYNOTE-021, 2016 2.04 [0.92; 4.52]
KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.20; 0.51]
KEYNOTE-042 (PDL1>1%), 2019 0.30 [0.23; 0.39]
MYSTIC (D ; all population), 2020 0.34 [0.24; 0.49]
MYSTIC (D ; PDL1>25%), 2020 0.36 [0.22; 0.61]
OAK (all population), 2016 0.23 [0.18; 0.31]
PACIFIC, 2017 2.99 [1.50; 5.98]
POPLAR, 2016 0.20 [0.11; 0.38]
0.41 [0.25 ; 0.68 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CAURAL (EXPLORATORY), 2019, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, PACIFIC, 2017, POPLAR, 2016 20 96% 10,698 moderate low TRAE leading to death (grade 5)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 078, 2019 0.61 [0.14; 2.77]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 4.33 [0.48; 39.16]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73]
IMpower-130 (all population), 2019 3.97 [0.49; 31.97]
IMpower-131 (ACnP), 2020 1.34 [0.30; 6.02]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.23 [0.50; 3.01]
JAVELIN Lung 200 (all population), 2018 0.19 [0.05; 0.68]
KEYNOTE-021, 2016 0.52 [0.05; 5.86]
KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.03; 3.11]
KEYNOTE-042 (PDL1>1%), 2019 0.90 [0.42; 1.92]
KEYNOTE-407, 2018 1.70 [0.61; 4.75]
MYSTIC (D ; all population), 2020 0.63 [0.11; 3.82]
MYSTIC (D ; PDL1>25%), 2020 0.95 [0.06; 15.32]
OAK (all population), 2016 0.47 [0.02; 14.16]
PACIFIC, 2017 1.15 [0.30; 4.49]
POPLAR, 2016 0.31 [0.03; 3.04]
0.89 [0.62 ; 1.28 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, PACIFIC, 2017, POPLAR, 2016 18 0% 10,142 moderate low TRAE leading to discontinuation (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.24; 4.26]
CheckMate 017, 2015 0.28 [0.09; 0.89]
CheckMate 026 (PDL1>1%), 2016 0.70 [0.41; 1.20]
CheckMate 078, 2019 0.66 [0.32; 1.37]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.89 [0.48; 1.63]
JAVELIN Lung 200 (all population), 2018 0.47 [0.29; 0.77]
KEYNOTE-021, 2016 0.76 [0.25; 2.35]
KEYNOTE-024 (PDL1>50%), 2016 0.64 [0.29; 1.44]
KEYNOTE-042 (PDL1>1%), 2019 0.95 [0.64; 1.39]
MYSTIC (D ; all population), 2020 0.55 [0.31; 0.99]
MYSTIC (D ; PDL1>25%), 2020 0.47 [0.21; 1.04]
POPLAR, 2016 0.07 [0.02; 0.29]
0.61 [0.46 ; 0.80 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, POPLAR, 2016 12 43% 5,509 moderate critical TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 017, 2015 0.23 [0.05; 1.13]
CheckMate 026 (PDL1>1%), 2016 1.24 [0.64; 2.40]
CheckMate 078, 2019 0.80 [0.33; 1.95]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.80 [0.38; 1.70]
KEYNOTE-021, 2016 4.44 [0.48; 40.91]
KEYNOTE-024 (PDL1>50%), 2016 0.86 [0.32; 2.29]
KEYNOTE-042 (PDL1>1%), 2019 1.09 [0.71; 1.66]
MYSTIC (D ; all population), 2020 1.28 [0.60; 2.75]
1.02 [0.78 ; 1.33 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 8 0% 4,035 moderate not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
0.49 [0.02 ; 14.75 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
KEYNOTE-021, 2016 4.32 [0.19; 97.73]
1.49 [0.30 ; 7.48 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016 5 0% 2,052 moderate serious Adrenal insufficiency TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
IMpower-131 (ACnP), 2020 2.00 [0.07; 59.91]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.06; 16.09]
JAVELIN Lung 200 (all population), 2018 1.86 [0.06; 55.60]
KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
KEYNOTE-189, 2018 0.50 [0.03; 8.00]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.49 [0.45 ; 4.88 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 7 0% 4,917 moderate serious Alopecia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65]
JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.54 [0.17 ; 1.65 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 11 0% 6,849 moderate critical Anaemia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.08 [0.00; 1.41]
CheckMate 017, 2015 0.12 [0.01; 2.29]
CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.13]
CheckMate 057, 2015 0.13 [0.02; 1.07]
CheckMate 078, 2019 0.15 [0.02; 1.47]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.34 [0.75; 2.38]
IMpower-130 (all population), 2019 1.62 [1.11; 2.36]
IMpower-131 (ACnP), 2020 1.09 [0.76; 1.58]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.05 [0.58; 1.89]
JAVELIN Lung 200 (all population), 2018 0.03 [0.00; 0.44]
KEYNOTE-021, 2016 0.79 [0.27; 2.29]
KEYNOTE-024 (PDL1>50%), 2016 0.08 [0.02; 0.28]
KEYNOTE-042 (PDL1>1%), 2019 0.04 [0.02; 0.12]
MYSTIC (D ; all population), 2020 0.01 [0.00; 0.19]
0.25 [0.12 ; 0.52 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 14 87% 7,633 moderate critical Arthralgia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.93 [0.02; 47.22]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.75 [0.17; 3.37]
JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.77 [0.25 ; 2.39 ] CheckMate 017, 2015, CheckMate 057, 2015, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-042 (PDL1>1%), 2019 6 0% 4,279 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.25 [0.01; 5.61]
CheckMate 017, 2015 0.10 [0.01; 1.76]
CheckMate 026 (PDL1>1%), 2016 0.12 [0.01; 2.31]
CheckMate 057, 2015 0.15 [0.02; 1.28]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.07; 17.15]
IMpower-130 (all population), 2019 1.48 [0.40; 5.52]
IMpower-131 (ACnP), 2020 0.77 [0.28; 2.10]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.45 [0.15; 1.30]
JAVELIN Lung 200 (all population), 2018 0.06 [0.01; 0.49]
KEYNOTE-042 (PDL1>1%), 2019 0.29 [0.08; 1.05]
MYSTIC (D ; all population), 2020 0.12 [0.01; 0.94]
PACIFIC, 2017 2.97 [0.15; 59.50]
0.40 [0.22 ; 0.72 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, PACIFIC, 2017 12 25% 7,424 moderate low Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.49 [0.02; 14.58]
0.86 [0.17 ; 4.48 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016 5 0% 2,003 moderate not evaluable Colitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 0.46 [0.01; 23.40]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
IMpower-131 (ACnP), 2020 8.08 [0.43; 153.53]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.53 [0.49; 13.10]
JAVELIN Lung 200 (all population), 2018 3.73 [0.17; 82.97]
KEYNOTE-024 (PDL1>50%), 2016 3.93 [0.18; 87.97]
KEYNOTE-042 (PDL1>1%), 2019 3.89 [0.43; 34.87]
KEYNOTE-189, 2018 3.01 [0.15; 60.33]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
2.75 [1.22 ; 6.22 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 057, 2015, CheckMate 078, 2019, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 12 0% 7,515 moderate low Constipation TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.23 [0.01; 5.17]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.26 [0.01; 5.89]
IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
IMpower-131 (ACnP), 2020 0.50 [0.02; 14.93]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
MYSTIC (D ; all population), 2020 0.48 [0.02; 14.24]
0.60 [0.22 ; 1.69 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 12 0% 6,382 moderate critical Cough TRAE (grade 3-4)detailed results PACIFIC, 2017 0.49 [0.01; 24.88]
0.49 [0.01 ; 24.88 ] PACIFIC, 2017 1 0% 709 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
CheckMate 017, 2015 0.98 [0.06; 15.91]
CheckMate 026 (PDL1>1%), 2016 0.24 [0.03; 2.19]
CheckMate 057, 2015 0.15 [0.01; 3.09]
CheckMate 078, 2019 0.46 [0.01; 23.40]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.43 [0.32; 6.48]
IMpower-130 (all population), 2019 0.86 [0.25; 2.95]
IMpower-131 (ACnP), 2020 3.41 [0.93; 12.49]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3.40 [0.93; 12.46]
JAVELIN Lung 200 (all population), 2018 0.07 [0.00; 1.15]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.12 [0.01; 2.27]
KEYNOTE-042 (PDL1>1%), 2019 0.53 [0.18; 1.60]
MYSTIC (D ; all population), 2020 0.24 [0.03; 2.13]
PACIFIC, 2017 0.25 [0.01; 7.35]
0.76 [0.41 ; 1.40 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, PACIFIC, 2017 15 27% 8,342 moderate critical Dermatitis acneiform TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
IMpower-131 (ACnP), 2020 6.05 [0.30; 121.16]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-189, 2018 1.00 [0.03; 29.86]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
1.45 [0.37 ; 5.61 ] CheckMate 057, 2015, CheckMate 078, 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 7 0% 4,135 moderate serious Diarrhoea TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 026 (PDL1>1%), 2016 0.59 [0.14; 2.48]
CheckMate 057, 2015 0.62 [0.10; 3.74]
CheckMate 078, 2019 0.93 [0.03; 27.74]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.15; 7.64]
EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
IMpower-130 (all population), 2019 1.03 [0.49; 2.14]
IMpower-131 (ACnP), 2020 1.44 [0.54; 3.83]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 5.64 [1.24; 25.63]
JAVELIN Lung 200 (all population), 2018 0.11 [0.01; 2.18]
KEYNOTE-021, 2016 0.52 [0.02; 15.84]
KEYNOTE-024 (PDL1>50%), 2016 3.00 [0.60; 15.11]
KEYNOTE-042 (PDL1>1%), 2019 4.87 [0.57; 41.77]
MYSTIC (D ; all population), 2020 0.95 [0.13; 6.81]
ORIENT-11, 2020 0.49 [0.01; 24.91]
PACIFIC, 2017 0.49 [0.07; 3.50]
1.13 [0.75 ; 1.69 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, EMPOWER lung1 (all population), 2021, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, ORIENT-11, 2020, PACIFIC, 2017 17 0% 9,436 moderate low Dizziness TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
1.02 [0.06 ; 16.40 ] CheckMate 017, 2015, KEYNOTE-021, 2016 2 0% 381 moderate not evaluable Dysgeusia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.93 [0.02; 47.22]
IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.86 [0.15 ; 4.96 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, IMpower-130 (all population), 2019, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016 5 0% 2,215 moderate not evaluable Dyspepsia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.46 [0.04; 5.13]
PACIFIC, 2017 2.97 [0.15; 59.50]
0.96 [0.15 ; 6.25 ] JAVELIN Lung 200 (all population), 2018, PACIFIC, 2017 2 0% 1,467 moderate not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Epistaxis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 8.09 [0.43; 153.59]
8.09 [0.43 ; 153.59 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
CheckMate 017, 2015 0.09 [0.01; 0.73]
CheckMate 026 (PDL1>1%), 2016 0.20 [0.06; 0.71]
CheckMate 057, 2015 0.21 [0.06; 0.74]
CheckMate 078, 2019 0.27 [0.06; 1.15]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.18 [0.65; 7.39]
IMpower-130 (all population), 2019 1.02 [0.53; 1.96]
IMpower-131 (ACnP), 2020 1.89 [0.75; 4.80]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.31 [0.57; 3.03]
JAVELIN Lung 200 (all population), 2018 0.09 [0.01; 0.71]
KEYNOTE-021, 2016 4.32 [0.19; 97.73]
KEYNOTE-024 (PDL1>50%), 2016 0.38 [0.07; 2.00]
KEYNOTE-042 (PDL1>1%), 2019 0.36 [0.09; 1.36]
MYSTIC (D ; all population), 2020 0.81 [0.27; 2.45]
0.59 [0.34 ; 1.01 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 14 57% 7,633 moderate low Febrile neutropenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.08 [0.00; 1.41]
CheckMate 017, 2015 0.03 [0.00; 0.58]
CheckMate 057, 2015 0.02 [0.00; 0.27]
IMpower-131 (ACnP), 2020 2.66 [1.10; 6.46]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.48 [0.85; 2.57]
JAVELIN Lung 200 (all population), 2018 0.01 [0.00; 0.20]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
0.25 [0.06 ; 1.08 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 057, 2015, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016 7 82% 3,274 moderate serious Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.19 [0.36; 3.94]
CheckMate 078, 2019 0.93 [0.03; 27.74]
1.15 [0.37 ; 3.58 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019 2 0% 1,023 moderate not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
1.00 [0.02 ; 50.55 ] IMpower-131 (ACnP), 2020 1 0% 668 NA not evaluable Headache TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.46 [0.02 ; 13.86 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 11.47 [1.48; 88.87]
IMpower-131 (ACnP), 2020 1.00 [0.06; 16.05]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 8.09 [0.43; 153.59]
KEYNOTE-042 (PDL1>1%), 2019 13.68 [0.77; 241.54]
KEYNOTE-189, 2018 4.02 [0.21; 76.41]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
4.51 [1.64 ; 12.39 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 8 0% 5,405 moderate not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 1.39 [0.14; 13.49]
1.39 [0.14 ; 13.49 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.23 [0.01; 6.90]
JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.44 [0.06 ; 3.38 ] CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 3 0% 1,806 moderate not evaluable Hypertension TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.57; 1.78]
JAVELIN Lung 200 (all population), 2018 1.86 [0.17; 20.62]
1.04 [0.59 ; 1.81 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018 2 0% 1,545 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
IMpower-131 (ACnP), 2020 2.00 [0.07; 59.91]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
ORIENT-11, 2020 0.49 [0.01; 24.91]
PACIFIC, 2017 0.49 [0.01; 24.88]
0.98 [0.35 ; 2.69 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 057, 2015, CheckMate 078, 2019, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, ORIENT-11, 2020, PACIFIC, 2017 14 0% 7,984 moderate critical Hypophysitis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
1.90 [0.40 ; 8.99 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 5 0% 3,670 moderate serious Hypothyroidism TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
IMpower-131 (ACnP), 2020 4.02 [0.18; 89.44]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
JAVELIN Lung 200 (all population), 2018 1.86 [0.06; 55.60]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 2.00 [0.09; 44.56]
MYSTIC (D ; all population), 2020 3.83 [0.17; 85.25]
ORIENT-11, 2020 0.49 [0.01; 24.91]
PACIFIC, 2017 0.99 [0.03; 29.48]
1.40 [0.57 ; 3.44 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, ORIENT-11, 2020, PACIFIC, 2017 16 0% 9,272 moderate critical Increase AST TRAE (grade 3-4)detailed results CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 0.46 [0.03; 7.42]
EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
KEYNOTE-021, 2016 1.05 [0.06; 17.21]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.35; 10.63]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.71 [0.65 ; 4.51 ] CheckMate 057, 2015, CheckMate 078, 2019, EMPOWER lung1 (all population), 2021, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, ORIENT-11, 2020 7 0% 4,301 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 3.51 [0.72; 17.07]
CheckMate 057, 2015 0.47 [0.02; 13.95]
CheckMate 078, 2019 0.46 [0.03; 7.42]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
JAVELIN Lung 200 (all population), 2018 3.73 [0.17; 82.97]
KEYNOTE-021, 2016 1.05 [0.06; 17.21]
KEYNOTE-042 (PDL1>1%), 2019 1.75 [0.58; 5.26]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.84 [0.91 ; 3.71 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, EMPOWER lung1 (all population), 2021, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, ORIENT-11, 2020 9 0% 5,589 moderate not evaluable Increased lacrimation (TRAE grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
0.99 [0.06 ; 15.95 ] CheckMate 057, 2015, KEYNOTE-021, 2016 2 0% 676 moderate not evaluable Increased lipase level TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
JAVELIN Lung 200 (all population), 2018 3.74 [0.42; 33.65]
3.14 [0.49 ; 19.89 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, JAVELIN Lung 200 (all population), 2018 2 0% 883 moderate not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
CheckMate 057, 2015 0.47 [0.02; 13.95]
CheckMate 078, 2019 0.46 [0.01; 23.40]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
JAVELIN Lung 200 (all population), 2018 5.64 [0.68; 47.10]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.16 [0.02; 1.33]
KEYNOTE-189, 2018 1.00 [0.03; 29.86]
0.92 [0.34 ; 2.48 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 057, 2015, CheckMate 078, 2019, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 10 0% 5,431 moderate low Leucopenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.16 [0.01; 3.32]
CheckMate 017, 2015 0.19 [0.02; 1.66]
CheckMate 026 (PDL1>1%), 2016 0.05 [0.00; 0.92]
CheckMate 057, 2015 0.02 [0.00; 0.32]
CheckMate 078, 2019 0.02 [0.00; 0.18]
IMpower-131 (ACnP), 2020 1.46 [0.72; 2.93]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.77 [0.51; 6.09]
JAVELIN Lung 200 (all population), 2018 0.05 [0.00; 0.78]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-042 (PDL1>1%), 2019 0.05 [0.00; 0.82]
0.19 [0.05 ; 0.66 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019 10 75% 5,548 moderate critical Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.22 [0.20 ; 7.53 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, EMPOWER lung1 (all population), 2021 4 0% 2,275 moderate not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.09 [0.00; 1.69]
JAVELIN Lung 200 (all population), 2018 0.11 [0.01; 2.18]
0.23 [0.04 ; 1.21 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 4 0% 2,103 moderate not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 1.87 [0.06; 55.99]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.18; 22.26]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.04 [0.28 ; 3.83 ] CheckMate 017, 2015, CheckMate 057, 2015, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-042 (PDL1>1%), 2019 6 0% 4,279 moderate not evaluable Myocarditis TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.41 [0.11 ; 18.42 ] JAVELIN Lung 200 (all population), 2018, KEYNOTE-042 (PDL1>1%), 2019 2 0% 2,009 moderate not evaluable Myositis TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
1.05 [0.16 ; 6.91 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-189, 2018 4 0% 2,366 moderate not evaluable Nausea TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.25 [0.01; 5.61]
CheckMate 017, 2015 0.24 [0.01; 5.45]
CheckMate 026 (PDL1>1%), 2016 0.19 [0.02; 1.67]
CheckMate 057, 2015 0.93 [0.13; 6.67]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.85 [0.22; 3.21]
IMpower-130 (all population), 2019 1.61 [0.52; 5.00]
IMpower-131 (ACnP), 2020 3.55 [0.73; 17.23]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.91 [0.80; 4.57]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-024 (PDL1>50%), 2016 0.16 [0.01; 3.21]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
MYSTIC (D ; all population), 2020 0.08 [0.00; 1.41]
PACIFIC, 2017 0.49 [0.01; 24.88]
0.75 [0.39 ; 1.44 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, PACIFIC, 2017 14 31% 7,849 moderate critical Nephritis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 6.06 [0.34; 109.04]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
1.96 [0.52 ; 7.32 ] EMPOWER lung1 (all population), 2021, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 7 0% 5,035 moderate serious Neutropenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.09 [0.01; 1.76]
CheckMate 017, 2015 0.01 [0.00; 0.15]
CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.25]
CheckMate 057, 2015 0.00 [0.00; 0.08]
CheckMate 078, 2019 0.03 [0.01; 0.15]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.19 [0.63; 2.24]
IMpower-130 (all population), 2019 1.22 [0.86; 1.72]
IMpower-131 (ACnP), 2020 0.93 [0.65; 1.35]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.27 [0.83; 1.94]
JAVELIN Lung 200 (all population), 2018 0.01 [0.00; 0.13]
KEYNOTE-021, 2016 2.14 [0.19; 24.25]
KEYNOTE-024 (PDL1>50%), 2016 0.02 [0.00; 0.35]
KEYNOTE-042 (PDL1>1%), 2019 0.02 [0.00; 0.14]
MYSTIC (D ; all population), 2020 0.02 [0.00; 0.18]
0.16 [0.08 ; 0.34 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 14 88% 7,633 moderate critical Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.63 [0.05 ; 8.17 ] CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 2 0% 1,313 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 2.00 [0.07; 59.91]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.03 [0.18; 89.56]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
KEYNOTE-189, 2018 2.00 [0.09; 44.56]
2.11 [0.47 ; 9.43 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 5 0% 3,617 moderate serious Pancytopenia TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 0.52 [0.02; 15.84]
0.52 [0.02 ; 15.84 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.93 [0.02; 47.22]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.50 [0.02; 14.97]
0.74 [0.09 ; 6.34 ] CheckMate 017, 2015, CheckMate 057, 2015, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 0% 1,602 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.15 [0.01; 3.09]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-131 (ACnP), 2020 2.01 [0.37; 11.06]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.23 [0.50; 3.01]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 1.76]
0.77 [0.35 ; 1.68 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, EMPOWER lung1 (all population), 2021, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-042 (PDL1>1%), 2019 8 9% 5,506 moderate not evaluable Peripheral oedema TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.47 [0.02; 13.95]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
0.50 [0.10 ; 2.46 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016 5 0% 2,224 moderate serious Peripheral sensory neuropathy TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 4.04 [0.45; 36.31]
JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
KEYNOTE-042 (PDL1>1%), 2019 0.08 [0.00; 1.43]
0.62 [0.05 ; 7.24 ] IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-042 (PDL1>1%), 2019 3 57% 2,677 moderate not evaluable Pneumonia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.06; 16.62]
JAVELIN Lung 200 (all population), 2018 0.09 [0.00; 1.68]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
0.53 [0.08 ; 3.32 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016 3 11% 1,004 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
CheckMate 017, 2015 1.98 [0.07; 59.45]
CheckMate 057, 2015 2.82 [0.29; 27.28]
CheckMate 078, 2019 3.74 [0.20; 71.10]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
IMpower-131 (ACnP), 2020 1.68 [0.40; 7.07]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3.04 [0.61; 15.15]
JAVELIN Lung 200 (all population), 2018 2.80 [0.29; 27.04]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-024 (PDL1>50%), 2016 3.97 [0.44; 35.97]
KEYNOTE-042 (PDL1>1%), 2019 20.97 [2.81; 156.36]
KEYNOTE-189, 2018 1.00 [0.30; 3.35]
MYSTIC (D ; all population), 2020 3.85 [0.43; 34.59]
ORIENT-11, 2020 0.98 [0.09; 10.96]
PACIFIC, 2017 0.65 [0.22; 1.90]
1.81 [1.11 ; 2.95 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, ORIENT-11, 2020, PACIFIC, 2017 16 0% 9,002 moderate critical Pruritic rash TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Pruritus generalised TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.02; 53.93]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
ORIENT-11, 2020 0.49 [0.01; 24.91]
PACIFIC, 2017 0.49 [0.01; 24.88]
0.91 [0.26 ; 3.15 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, ORIENT-11, 2020, PACIFIC, 2017 9 0% 5,132 moderate serious Pyrexia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
CheckMate 057, 2015 0.93 [0.02; 47.22]
JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.69 [0.13 ; 3.61 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018, KEYNOTE-024 (PDL1>50%), 2016 5 0% 2,407 moderate serious Rash TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.06; 16.62]
CheckMate 017, 2015 0.24 [0.01; 5.45]
CheckMate 026 (PDL1>1%), 2016 1.98 [0.18; 21.94]
CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 2.79 [0.14; 56.11]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.13 [0.07; 64.04]
EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
IMpower-131 (ACnP), 2020 2.01 [0.18; 22.23]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.59 [0.99; 21.40]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
ORIENT-11, 2020 0.16 [0.02; 1.56]
PACIFIC, 2017 0.99 [0.03; 29.48]
1.75 [0.91 ; 3.35 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, ORIENT-11, 2020, PACIFIC, 2017 15 0% 8,218 moderate low Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
CheckMate 078, 2019 0.46 [0.01; 23.40]
1.06 [0.08 ; 13.83 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019 2 0% 1,023 moderate not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 12.07 [0.67; 217.19]
CheckMate 078, 2019 6.60 [0.37; 116.99]
8.91 [1.16 ; 68.41 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019 2 0% 1,023 moderate not evaluable Sepsis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
JAVELIN Lung 200 (all population), 2018 0.23 [0.01; 5.14]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
0.91 [0.14 ; 6.07 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016 3 0% 1,666 moderate not evaluable Severe skin reaction TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
KEYNOTE-021, 2016 1.05 [0.06; 17.21]
KEYNOTE-024 (PDL1>50%), 2016 12.12 [0.67; 218.98]
KEYNOTE-042 (PDL1>1%), 2019 10.81 [1.39; 83.96]
KEYNOTE-189, 2018 1.00 [0.30; 3.35]
2.45 [0.73 ; 8.21 ] IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 5 30% 2,951 moderate not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 5.00 [0.58; 43.09]
CheckMate 078, 2019 2.79 [0.14; 56.11]
4.10 [0.71 ; 23.60 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019 2 0% 1,023 moderate not evaluable Skin exfoliation TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
CheckMate 057, 2015 0.23 [0.01; 5.17]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
KEYNOTE-021, 2016 0.52 [0.02; 15.84]
KEYNOTE-024 (PDL1>50%), 2016 0.24 [0.01; 5.39]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.72 [0.24 ; 2.14 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 8 0% 4,431 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.04 [0.01; 0.31]
IMpower-130 (all population), 2019 1.52 [0.83; 2.79]
IMpower-131 (ACnP), 2020 1.16 [0.68; 2.00]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.94 [0.47; 1.89]
KEYNOTE-021, 2016 1.05 [0.14; 7.73]
KEYNOTE-024 (PDL1>50%), 2016 0.06 [0.00; 1.02]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 0.75]
MYSTIC (D ; all population), 2020 0.03 [0.00; 0.42]
0.44 [0.19 ; 1.01 ] CheckMate 026 (PDL1>1%), 2016, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 8 74% 5,087 moderate serious 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-15 12:25 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258
